Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. Its portfolio includes treatments for cardiovascular, oncology, hematology, immunology, and fibrotic diseases.
Bristol-Myers Squibb Company operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for BMY.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). BMY Stock Intelligence Report. [stoxpulse.com/stocks/bmy]
Disclaimer: The information on this page about Bristol-Myers Squibb Company (BMY) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Bristol-Myers Squibb Company.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 10%
Mar 31
Short bought 8K shares
2d ago
Short sold 4K shares
2d ago
Billionaire Izzy Englander Just Made a Big Bet on ...
2h ago
AGEN Early Access Revenues Signal a New Path Ahead...
2h ago
StoxPulse AI results for BMY: Pulse Score 47/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$117.05B
P/E Ratio
15.6
EPS
$0.53
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Jun 25
+35.0%
Sep 25
+6.9%
Dec 25
+11.9%
Mar 26
+10.4%
Beat estimates 4 of 4 quarters (100%)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. Its portfolio includes treatments for cardiovascular, oncology, hematology, immunology, and fibrotic diseases.
Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock
AGEN Early Access Revenues Signal a New Path Ahead of Approval
Is Agenus Stock a Hold Amid Valuation and Funding Risks?
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
Investors are taking profits ahead of SpaceX IPO, says Capital Wealth's Kevin Simpson
Early Detection in Brazil Is a Game Changer for Lung Cancer Care
Bristol-Myers Squibb Co (NYSE:BMY): High Yield and Solid Profitability, but Growth Concerns Loom
Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative